• Je něco špatně v tomto záznamu ?

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

G. Salles, J. Duell, E. González Barca, O. Tournilhac, W. Jurczak, AM. Liberati, Z. Nagy, A. Obr, G. Gaidano, M. André, N. Kalakonda, M. Dreyling, J. Weirather, M. Dirnberger-Hertweck, S. Ambarkhane, G. Fingerle-Rowson, K. Maddocks,

. 2020 ; 21 (7) : 978-988. [pub] 20200605

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20024930
E-zdroje Online Plný text

NLK ProQuest Central od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci

Odkazy

PubMed 32511983
DOI 10.1016/s1470-2045(20)30225-4
Knihovny.cz E-zdroje

BACKGROUND: Patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem-cell transplantation have poor outcomes and few treatment options. Tafasitamab (MOR208) is an Fc-enhanced, humanised, anti-CD19 monoclonal antibody that has shown preclinical and single-agent activity in patients with relapsed or refractory B-cell malignancies. Preclinical data suggested that tafasitamab might act synergistically with lenalidomide. We aimed to assess the antitumour activity and safety of tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for autologous stem-cell transplantation. METHODS: In this multicentre, open-label, single-arm, phase 2 study (L-MIND), patients older than 18 years with histologically confirmed diffuse large B-cell lymphoma, who relapsed or had refractory disease after previous treatment with one to three systemic regimens (with at least one anti-CD20 therapy), were not candidates for high-dose chemotherapy and subsequent autologous stem-cell transplantation, had an Eastern Cooperative Oncology Group performance status of 0-2, and had measurable disease at baseline were recruited from 35 academic and community hospitals in ten countries. Patients received coadministered intravenous tafasitamab (12 mg/kg) and oral lenalidomide (25 mg/day) for up to 12 cycles (28 days each), followed by tafasitamab monotherapy (in patients with stable disease or better) until disease progression. The primary endpoint was the proportion of patients with an objective response (centrally assessed), defined as a complete or partial response according to the 2007 International Working Group response criteria for malignant lymphoma. Antitumour activity analyses are based on all patients who received at least one dose of both tafasitamab and lenalidomide; safety analyses are based on all patients who received at least one dose of either study medication. Recruitment is complete, and the trial is in follow-up. This trial is registered with ClinicalTrials.gov, NCT02399085. FINDINGS: Between Jan 18, 2016, and Nov 15, 2017, 156 patients were screened: 81 were enrolled and received at least one dose of either study medication, and 80 received at least one dose of both tafasitamab and lenalidomide. Median follow-up was 13·2 months (IQR 7·3-20·4) as of data cutoff on Nov 30, 2018. 48 (60%; 95% CI 48-71) of 80 patients who received tafasitamab plus lenalidomide had an objective response: 34 (43%; 32-54) had a complete response and 14 (18%; 10-28) had a partial response. The most common treatment-emergent adverse events of grade 3 or worse were neutropenia (39 [48%] of 81 patients), thrombocytopenia (14 [17%]), and febrile neutropenia (ten [12%]). Serious adverse events occurred in 41 (51%) of 81 patients. The most frequently reported serious adverse events (in two or more patients) were pneumonia (five [6%]), febrile neutropenia (five [6%]), pulmonary embolism (three [4%]), bronchitis (two [2%]), atrial fibrillation (two [2%]), and congestive cardiac failure (two [2%]). INTERPRETATION: Tafasitamab in combination with lenalidomide was well tolerated and resulted in a high proportion of patients with relapsed or refractory diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation having a complete response, and might represent a new therapeutic option in this setting. FUNDING: MorphoSys.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20024930
003      
CZ-PrNML
005      
20201222153620.0
007      
ta
008      
201125s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(20)30225-4 $2 doi
035    __
$a (PubMed)32511983
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Salles, Gilles $u Hématologie, Hospices Civils de Lyon and Université de Lyon, Lyon, France. Electronic address: gilles.salles@chu-lyon.fr.
245    10
$a Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study / $c G. Salles, J. Duell, E. González Barca, O. Tournilhac, W. Jurczak, AM. Liberati, Z. Nagy, A. Obr, G. Gaidano, M. André, N. Kalakonda, M. Dreyling, J. Weirather, M. Dirnberger-Hertweck, S. Ambarkhane, G. Fingerle-Rowson, K. Maddocks,
520    9_
$a BACKGROUND: Patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem-cell transplantation have poor outcomes and few treatment options. Tafasitamab (MOR208) is an Fc-enhanced, humanised, anti-CD19 monoclonal antibody that has shown preclinical and single-agent activity in patients with relapsed or refractory B-cell malignancies. Preclinical data suggested that tafasitamab might act synergistically with lenalidomide. We aimed to assess the antitumour activity and safety of tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for autologous stem-cell transplantation. METHODS: In this multicentre, open-label, single-arm, phase 2 study (L-MIND), patients older than 18 years with histologically confirmed diffuse large B-cell lymphoma, who relapsed or had refractory disease after previous treatment with one to three systemic regimens (with at least one anti-CD20 therapy), were not candidates for high-dose chemotherapy and subsequent autologous stem-cell transplantation, had an Eastern Cooperative Oncology Group performance status of 0-2, and had measurable disease at baseline were recruited from 35 academic and community hospitals in ten countries. Patients received coadministered intravenous tafasitamab (12 mg/kg) and oral lenalidomide (25 mg/day) for up to 12 cycles (28 days each), followed by tafasitamab monotherapy (in patients with stable disease or better) until disease progression. The primary endpoint was the proportion of patients with an objective response (centrally assessed), defined as a complete or partial response according to the 2007 International Working Group response criteria for malignant lymphoma. Antitumour activity analyses are based on all patients who received at least one dose of both tafasitamab and lenalidomide; safety analyses are based on all patients who received at least one dose of either study medication. Recruitment is complete, and the trial is in follow-up. This trial is registered with ClinicalTrials.gov, NCT02399085. FINDINGS: Between Jan 18, 2016, and Nov 15, 2017, 156 patients were screened: 81 were enrolled and received at least one dose of either study medication, and 80 received at least one dose of both tafasitamab and lenalidomide. Median follow-up was 13·2 months (IQR 7·3-20·4) as of data cutoff on Nov 30, 2018. 48 (60%; 95% CI 48-71) of 80 patients who received tafasitamab plus lenalidomide had an objective response: 34 (43%; 32-54) had a complete response and 14 (18%; 10-28) had a partial response. The most common treatment-emergent adverse events of grade 3 or worse were neutropenia (39 [48%] of 81 patients), thrombocytopenia (14 [17%]), and febrile neutropenia (ten [12%]). Serious adverse events occurred in 41 (51%) of 81 patients. The most frequently reported serious adverse events (in two or more patients) were pneumonia (five [6%]), febrile neutropenia (five [6%]), pulmonary embolism (three [4%]), bronchitis (two [2%]), atrial fibrillation (two [2%]), and congestive cardiac failure (two [2%]). INTERPRETATION: Tafasitamab in combination with lenalidomide was well tolerated and resulted in a high proportion of patients with relapsed or refractory diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation having a complete response, and might represent a new therapeutic option in this setting. FUNDING: MorphoSys.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $7 D061067
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a chemorezistence $x účinky léků $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a lenalidomid $x aplikace a dávkování $7 D000077269
650    _2
$a difúzní velkobuněčný B-lymfom $x farmakoterapie $x patologie $7 D016403
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $x farmakoterapie $x patologie $7 D009364
650    _2
$a prospektivní studie $7 D011446
650    12
$a záchranná terapie $7 D016879
650    _2
$a míra přežití $7 D015996
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Duell, Johannes $u Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany.
700    1_
$a González Barca, Eva $u Department of Hematology, Institut Catalá d'Oncologia, Hospital Duran i Reynals, Institut d'Investigacio Biomedica de Bellvitge, Barcelona, Spain.
700    1_
$a Tournilhac, Olivier $u Service d'Hématologie Clinique et de Thérapie Cellulaire, Centres Hospitalier Universitaire Estaing, Clermont-Ferrand, France.
700    1_
$a Jurczak, Wojciech $u Maria Skłodowska-Curie National Institute of Oncology, Kraków, Poland.
700    1_
$a Liberati, Anna Marina $u Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria di Terni, Terni, Italy.
700    1_
$a Nagy, Zsolt $u 1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
700    1_
$a Obr, Aleš $u Department of Hemato-Oncology, Palacký University and University Hospital, Olomouc, Czech Republic.
700    1_
$a Gaidano, Gianluca $u Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale Amedeo Avogadro, Novara, Italy.
700    1_
$a André, Marc $u Department of Haematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium.
700    1_
$a Kalakonda, Nagesh $u Molecular and Clinical Cancer Medicine, University of Liverpool and The Clatterbridge Cancer Centre, Liverpool, UK.
700    1_
$a Dreyling, Martin $u Department of Medicine III, University Hospital Groβhadern, Ludwig Maximilians University, Munich, Germany.
700    1_
$a Weirather, Johannes $u MorphoSys, Planegg, Germany.
700    1_
$a Dirnberger-Hertweck, Maren $u MorphoSys, Planegg, Germany.
700    1_
$a Ambarkhane, Sumeet $u MorphoSys, Planegg, Germany.
700    1_
$a Fingerle-Rowson, Günter $u MorphoSys, Planegg, Germany.
700    1_
$a Maddocks, Kami $u Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
773    0_
$w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 21, č. 7 (2020), s. 978-988
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32511983 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222153616 $b ABA008
999    __
$a ok $b bmc $g 1599075 $s 1115616
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 21 $c 7 $d 978-988 $e 20200605 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace